Immunotherapy (IO) options can induce durable responses in patients with BRAF-negative metastatic melanoma.
Melanoma News
Nivolumab/Relatlimab Elicit IC Activity in Anti–PD-L1–Refractory Melanoma Brain Mets
Nivolumab (Opdivo) plus relatlimab demonstrated intracranial activity in patients with anti–PD-(L)1 refractory melanoma who have melanoma brain metastases,
Relatlimab Shows Comparable Efficacy to Ipilimumab in Advanced Melanoma
The addition of relatlimab (Opdualag) to nivolumab (Opdivo) exhibited comparable efficacy outcomes vs ipilimumab (Yervoy) and nivolumab in patients with advanced melanoma
Lifileucel Sustains Long-Term Responses and Survival in Advanced Melanoma
Lifileucel therapy achieved a 31.4% objective response rate in advanced melanoma patients, with 5.9% complete responses and 25.5% partial responses.